Substance P Peptide for Spinal Cord Injury Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for spinal cord injuries are inadequate, with methylprednisolone being the only recognized treatment within 24 hours of injury, but its effectiveness is limited, and there are no effective long-term solutions to improve neurological outcomes, as they fail to address the underlying causes of apoptosis and inflammation.
Innovation Solution
A composition comprising Substance P as an active ingredient to treat or prevent spinal cord injuries, inhibit apoptosis, decrease microglia activity, and reduce inflammation, which can be administered in various forms such as tablets, capsules, or injectable liquids, targeting traumatic and non-traumatic injuries, including those caused by vascular dysfunction or degenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If methylprednisolone treatment is administered within 24 hours after spinal cord injury, then damage to nervous tissue is decreased, but the curative power is insignificant and the treatment utility remains controversial
Solution Approach 1:
The patent changes the chemical parameter from methylprednisolone to Substance P, a different class of compound with neuroprotective properties. This parameter change aims to achieve more reliable treatment effectiveness while avoiding the limitations of methylprednisolone, such as significant side effects and controversial utility. Substance P is administered at optimized doses (e.g., 1-100 μg/kg) to maximize therapeutic effect while minimizing adverse reactions.
2Duration of action of stationary object
If current treatments are used for spinal cord injury, then acute phase damage is addressed, but long-term neurological outcomes are not improved and underlying causes of apoptosis and inflammation are not addressed
Solution Approach 1:
The patent applies preliminary action by administering Substance P immediately after spinal cord injury to prevent the cascade of pathological events before they fully develop. Substance P treatment is given in the acute phase to preemptively protect neurons from excitotoxicity, oxidative stress, and apoptosis that would otherwise progress unchecked. This early intervention aims to alter the disease trajectory and improve long-term neurological outcomes by addressing underlying causes before they become irreversible.
3Reliability
If no effective treatment is available for spinal cord injury, then neurological outcomes remain poor, but the lack of treatment options limits further therapeutic intervention
Solution Approach 1:
The patent demonstrates universality by showing that Substance P has multiple therapeutic functions in spinal cord injury: it reduces inflammation, inhibits apoptosis, protects neurons from excitotoxicity, and promotes neuroregeneration. This single compound addresses multiple pathological mechanisms simultaneously, providing a versatile treatment option that can be applied across different injury severities and time points, thereby expanding treatment availability while improving neurological outcomes.
Data Source
AI summary
The present invention relates to a novel use of substance P. The substance P of the present invention exhibits effects of decreasing microglia activity, decreasing proinflammatory cytokines, inhibiting apoptosis, etc. The substance P of the present invention effectively treats degenerative central nervous system diseases or disorders such as a spinal cord injury caused by a traumatic injury (flexion injury, vertical compression injury, hyperextension injury, flexion-rotation injury) and by a non-traumatic injury (vascular dysfunction, arthritis, or degenerative arthritis), Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, depressive disorder, epilepsy, etc.